United Therapeutics Corporation
Moat Score — United Therapeutics Corporation
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | United Therapeutics holds deep patent and formulation know-how across every treprostinil delivery format (inhaled, subcutaneous/IV, oral), plus genuinely frontier IP in gene-edited pig organ xenotransplantation and 3D-printed lung alternatives that almost no other company possesses at this stage of development. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | The company is not a low-cost producer; it maintains deliberately expensive two-plus-year inventory buffers on key drugs and relies on specialized third-party manufacturers (MannKind, Simtra, Eli Lilly), prioritizing supply reliability over cost efficiency. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the maker of life-sustaining therapies for a rare, severe disease with few substitutes, United Therapeutics has historically exercised strong pricing power on Tyvaso and Remodulin, though this is beginning to face pressure from generic settlements and Merck's newly approved Winrevair. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in a specialty pharmaceutical business selling injectable and inhaled drugs to PAH patients through specialty pharmacies and hospitals; more patients using Tyvaso do not make the drug more valuable to any other patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Patients stabilized on a particular treprostinil delivery format face real clinical risk and disruption in switching therapies, and prescribers who have built treatment protocols around Tyvaso/Remodulin have real inertia, though this is bounded by the availability of competing PAH drug classes. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The PAH market is a limited, well-defined rare-disease population that does not support unlimited competitors; United Therapeutics' scale advantage here is real but is increasingly being tested by the entry of Merck's Winrevair and Liquidia's generic-class inhaled product. |